All regulations
Nonrulemaking
FDA
FDA-2025-P-6625
Requests that the FDA declare that the drug product Metformin Hydrochloride Tablets, 375 mg, is suitable for consideration in an Abbreviated New Drug Application.
Documents
8
Comments
0
Description
CLOSED
Key Dates
Comment Period OpensDec 3, 2025
Documents
| Type | Title | Status |
|---|---|---|
Other |
Keywords
CDER
Suitability Petition
Hyman Phelps and McNamara PC
declare that the drug product
Metformin Hydrochloride Tablets 375 mg
is suitable for consideration
in an Abbreviated New Drug Application
CLOSED
Data from Regulations.gov